NZ608239A - Aqueous drug delivery system comprising off - flavor masking agent - Google Patents

Aqueous drug delivery system comprising off - flavor masking agent

Info

Publication number
NZ608239A
NZ608239A NZ608239A NZ60823911A NZ608239A NZ 608239 A NZ608239 A NZ 608239A NZ 608239 A NZ608239 A NZ 608239A NZ 60823911 A NZ60823911 A NZ 60823911A NZ 608239 A NZ608239 A NZ 608239A
Authority
NZ
New Zealand
Prior art keywords
masking agent
delivery system
drug delivery
aqueous drug
flavor masking
Prior art date
Application number
NZ608239A
Other languages
English (en)
Inventor
Kyle A Reed
Original Assignee
Bev Rx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bev Rx Inc filed Critical Bev Rx Inc
Publication of NZ608239A publication Critical patent/NZ608239A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/84—Flavour masking or reducing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ608239A 2010-09-13 2011-09-13 Aqueous drug delivery system comprising off - flavor masking agent NZ608239A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38209810P 2010-09-13 2010-09-13
PCT/US2011/051386 WO2012037117A1 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system comprising off - flavor masking agent
US13/231,150 US9018193B2 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system

Publications (1)

Publication Number Publication Date
NZ608239A true NZ608239A (en) 2015-05-29

Family

ID=44674918

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ608239A NZ608239A (en) 2010-09-13 2011-09-13 Aqueous drug delivery system comprising off - flavor masking agent

Country Status (15)

Country Link
US (4) US9018193B2 (https=)
EP (2) EP3210597A1 (https=)
JP (2) JP5890951B2 (https=)
KR (1) KR20140007798A (https=)
CN (1) CN103209684A (https=)
AU (1) AU2011302293B2 (https=)
BR (1) BR112013005987A2 (https=)
CA (1) CA2811202A1 (https=)
IL (1) IL225149B (https=)
MY (1) MY162175A (https=)
NZ (1) NZ608239A (https=)
PH (1) PH12013500477A1 (https=)
RU (1) RU2013116336A (https=)
SG (2) SG10201507554RA (https=)
WO (1) WO2012037117A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389461B2 (en) 2015-10-30 2022-07-19 Cmp Development Llc Spironolactone aqueous compositions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3142644A1 (en) * 2014-05-16 2017-03-22 Vivus, Inc. Orally administrable formulations for the controlled release of a pharmacologically active agent
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
CN107406370A (zh) * 2014-12-09 2017-11-28 以西结·戈兰 酒精饮料替代品
DK3230255T3 (da) 2014-12-09 2020-06-22 Ezekiel Golan Regulatorer af uhæmmet adfærd
KR102055490B1 (ko) * 2015-04-07 2019-12-12 닛산 가가쿠 가부시키가이샤 액체 배지 조성물의 제조 방법, 및 이의 제조 장치 및 키트
WO2018048779A1 (en) * 2016-09-06 2018-03-15 Children's Medical Center Corporation Topical trpv1 antagonists and methods and compositions thereof
KR20240005122A (ko) * 2016-09-16 2024-01-11 사이덱스 파마슈티칼스, 인크. 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
WO2019140403A1 (en) * 2018-01-15 2019-07-18 Seattle Gummy Company Semi-solid anti-histamine compositions and methods of making and using thereof
US10828286B2 (en) * 2018-05-24 2020-11-10 Gm Pharmaceuticals, Inc. Niacin and berberine compositions and methods of use thereof
MX2020013689A (es) * 2018-06-29 2021-05-12 Roquette Freres Hidroxipropil-?-ciclodextrina novedosa y proceso para la producción de esta.
JP2020019731A (ja) * 2018-07-31 2020-02-06 日本食品化工株式会社 アムロジピンベシル酸塩の苦味抑制剤
JP6711875B2 (ja) * 2018-08-29 2020-06-17 日本食品化工株式会社 マクロライド化合物の苦味抑制剤
US20210401017A1 (en) * 2020-12-11 2021-12-30 Jiangnan University Preparation Method of Starch-based Double Emulsion Embedding Fat-soluble Functional Factors
US11452690B1 (en) * 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
GR1010732B (el) * 2023-06-02 2024-07-25 Ιουλια Κλεωνος Τσετη Φαρμακευτικη συνθεση ιβουπροφαινης και παρακεταμολης για απο του στοματος χορηγηση
CN119185191A (zh) * 2024-09-12 2024-12-27 广东心宝药业科技有限公司 一种口服液药物口感的控制方法及系统

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
GB9226391D0 (en) 1992-12-18 1993-02-10 Cpc International Inc Xanthan gelling agents
US5362860A (en) 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5651980A (en) 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles
US6319535B1 (en) 1995-11-28 2001-11-20 Laurence J. Shaw Confections that “swim” in a carbonated beverage
EP0936877B1 (en) 1996-10-09 2003-11-26 Givaudan SA Process for preparing beads as food additive
AU5453198A (en) 1996-11-29 1998-06-22 Monsanto Company Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients
US5776431A (en) 1997-03-26 1998-07-07 Galat; Alexander Water-soluble aspirin composition
KR100693266B1 (ko) 1997-03-28 2007-03-27 에자이 가부시키가이샤 쓴맛 등을 은폐한 경구 약제
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
WO1999003474A1 (de) 1997-07-15 1999-01-28 Walter Burghart Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen
AU744328B2 (en) 1997-10-31 2002-02-21 Cp Kelco Aps Controlled release compositions comprising gellan gum gels
US6572898B2 (en) 1999-05-21 2003-06-03 Pts Labs Llc Electrolyte gels for maintaining hydration and rehydration
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
ES2294036T3 (es) 2000-10-16 2008-04-01 Pepsico, Inc. Procedimiento de preparacion de bebidas suplementadas con calcio.
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
CN1638804A (zh) 2002-03-04 2005-07-13 美德阿利克斯株式会社 在生物体内相转移的液态基质以及液态口服制剂
WO2004009053A2 (en) 2002-07-19 2004-01-29 Vitalstate Canada Ltd. Oral delivery system containing a gel matrix and liposomes
SI1553927T1 (sl) 2002-09-11 2010-12-31 Elan Pharma Int Ltd Z gelom stabilizirani nanodeläśni sestavki uäśinkovine
US20060018972A1 (en) 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
EP1669090B1 (en) 2003-09-12 2016-03-30 Ryukakusan Co. Ltd. Bitterness-masking particulate jelly beverage
WO2005037264A1 (ja) 2003-10-17 2005-04-28 Medrx Co., Ltd. ビグアナイド系薬剤を含有するゼリー製剤
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
ATE516019T1 (de) 2004-05-11 2011-07-15 Egalet Ltd Quellbare dosierform mit gellan-gummit
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
EP1771161B1 (en) 2004-07-22 2010-04-21 Bend Research, Inc Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20070092561A1 (en) 2005-06-24 2007-04-26 Don Milne Water-Soluble Aspirin Composition
US8715731B2 (en) 2006-03-22 2014-05-06 Isp Investments Inc. Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
CN101588790A (zh) 2006-07-06 2009-11-25 艾博特呼吸有限责任公司 超多孔水凝胶
US20100015227A1 (en) 2006-07-14 2010-01-21 Amos Nussinovitch Dried electrified hydrocolloid gels having unique structure and porosity
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
JP5205909B2 (ja) * 2006-10-18 2013-06-05 大正製薬株式会社 粘膜適用液剤
JP5048398B2 (ja) * 2007-06-13 2012-10-17 大蔵製薬株式会社 抗真菌剤の医薬組成物
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
KR100937625B1 (ko) 2007-08-10 2010-01-20 주식회사 제닉 가용성 웹 공극필름 및 이의 제조방법
US9186640B2 (en) 2007-08-28 2015-11-17 Pepsico, Inc. Delivery and controlled release of encapsulated lipophilic nutrients
US20100215740A1 (en) * 2007-10-10 2010-08-26 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009047859A1 (ja) 2007-10-12 2009-04-16 Ryukakusan Co. Ltd. 薬服用粒状ゼリー飲料及びその製造方法
US20090104251A1 (en) 2007-10-22 2009-04-23 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
CN101951923B (zh) 2007-12-20 2013-10-30 N.V.努特里奇亚 含核苷酸/核苷的液态产品
EP2249802B1 (en) 2008-02-06 2013-01-16 University of East Anglia Composition and method for assisting swallowing
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
WO2009130704A1 (en) 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
US9414615B2 (en) * 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389461B2 (en) 2015-10-30 2022-07-19 Cmp Development Llc Spironolactone aqueous compositions
US11395828B2 (en) 2015-10-30 2022-07-26 Cmp Development Llc Spironolactone aqueous compositions

Also Published As

Publication number Publication date
PH12013500477A1 (en) 2018-01-17
US20150209435A1 (en) 2015-07-30
WO2012037117A1 (en) 2012-03-22
KR20140007798A (ko) 2014-01-20
MY162175A (en) 2017-05-31
JP2016153401A (ja) 2016-08-25
SG188509A1 (en) 2013-04-30
BR112013005987A2 (pt) 2019-09-24
SG10201507554RA (en) 2015-10-29
CA2811202A1 (en) 2012-03-22
US9789191B2 (en) 2017-10-17
CN103209684A (zh) 2013-07-17
AU2011302293A1 (en) 2013-04-04
JP6263699B2 (ja) 2018-01-24
US20200114011A1 (en) 2020-04-16
EP2616046A1 (en) 2013-07-24
RU2013116336A (ru) 2014-10-20
JP2013537891A (ja) 2013-10-07
AU2011302293B2 (en) 2015-11-26
JP5890951B2 (ja) 2016-03-22
EP2616046B1 (en) 2016-08-31
EP3210597A1 (en) 2017-08-30
IL225149B (en) 2018-05-31
US9018193B2 (en) 2015-04-28
US20120122823A1 (en) 2012-05-17
US20180256725A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
SA112330855B1 (ar) تركيبة صيدلانية سريعة الذوبان
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
UY33076A (es) Microcápsulas de fexofenadina y composiciones que las contienen
WO2010121177A3 (en) Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
MX2009004439A (es) Composicion de ibuprofeno.
EP2578234A4 (en) SUGAR-REAGENT GEL AND MEDICAMENT ADMINISTRATION DEVICE
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
MX2012013021A (es) Formulaciones resistentes a alcohol.
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EA201391689A1 (ru) Система доставки лекарственного средства
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
HRP20181517T1 (hr) Sustav dostave lijeka za administraciju u vodi topljive, kationske i amfifilne farmaceutski aktivne tvari
MX2023008206A (es) Sistema de suministro de farmacos gastrorretentivos.
MX2010006170A (es) Composicion farmaceutica para la limpieza del intestino.
NZ707033A (en) Dispersible nimorazole tablet
WO2013069925A3 (ko) 안구 약물 전달 시스템 및 이에 사용되는 미소 기포의 제조 방법
UA100374C2 (ru) Лекарственное средство в виде порошка в саше с муколитическими и отхаркивающими свойствами
EA201992463A1 (ru) Система доставки лекарственного средства
UA97524C2 (ru) Лекарственный препарат противосудорожного действия топиромата в форме таблеток и его кристаллический состав
LT2009004A (en) New combination of active ingredients containing a non steroidal antiimplamatotory drug and a colchicoside derivative
SA515360445B1 (ar) قرص قابل للتشتيت

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2016 BY AJ PARK

Effective date: 20151223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2017 BY THOMSON REUTERS

Effective date: 20160909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2018 BY AJ PARK

Effective date: 20170912

LAPS Patent lapsed